Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients

Clémentine Sarkozy,Mary Bridgid Callanan,Catherine Thieblemont,Lucie Obéric,Barbara Burroni,Krimo Bouabdallah,Ghandi Damaj,Benoit Tessoulin,Vincent Ribrag,Roch Huout,Franck Morschhauser,Samuel Griolet,Clémentine Joubert,Victoria Cacheux,Vincent Delwail,Violaine Safar,Remy Gressin,Morgane Cheminant,Marie-Helene Delfau-Larue,Olivier Hermine,Elizabeth A. Macintyre,Steven Le Gouill

DOI: https://doi.org/10.1182/blood.2024023944

IF: 20.3

2024-04-28

Blood

Abstract:Obinutuzumab can safely be used in combination with chemotherapy and in maintenance after ASCT as frontline therapy in MCL patients. Obinutuzumab provides better disease control than Rituximab without additional toxicity in MCL. Obinutuzumab (O) and Rituximab (R) are two CD antibodies that have never been compared in a prospective randomised trial in mantle cell lymphoma (MCL). Herein, we report the long-term outcome of the LYMA-101 (NCT02896582) trial, in which newly diagnosed MCL patients were treated with chemotherapy plus O before transplantation followed by O maintenance (O group). We then compared these patients to those treated with the same treatment design with Rituximab instead of O (R group) (NCT00921414). A propensity score matching (PSM) was used to compare the two populations (O vs R groups) in terms of MRD at the end of induction (EOI), PFS and OS. In LYMA-101, the estimated five-year PFS and OS since inclusion (n=85) were 83.4% (95%CI: 73.5-89.8%) and 86.9% (95%CI: 77.6-92.5%), respectively. At EOI, patients treated in the O group had more frequent bone marrow MRD negativity than those treated in the R group (83.1% vs 63.4% Chi2 p=0.007). The PSM resulted in 2 sets of 82 patients with comparable characteristics at inclusion. From treatment initiation, the O group had a longer estimated five-year PFS (p=0.029; 82.8% versus 66.6%, HR 1.99, IC95 1.05-3.76) and OS (p=0.039; 86.4% versus 71.4% (HR 2.08, IC95 1.01-4.16) compared to the R group. Causes of death were comparable in the 2 groups, the most common cause being lymphoma. Obinutuzumab prior to transplantation and in maintenance provides better disease control and enhances PFS and OS, as compared to Rituximab in transplant-eligible MCL patients.

hematology